661 related articles for article (PubMed ID: 34324152)
1. Synthesis and Identification of Novel Potential Molecules Against COVID-19 Main Protease Through Structure-Guided Virtual Screening Approach.
El Bakri Y; Anouar EH; Ahmad S; Nassar AA; Taha ML; Mague JT; El Ghayati L; Essassi EM
Appl Biochem Biotechnol; 2021 Nov; 193(11):3602-3623. PubMed ID: 34324152
[TBL] [Abstract][Full Text] [Related]
2. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
[TBL] [Abstract][Full Text] [Related]
3. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
[TBL] [Abstract][Full Text] [Related]
4. Insight into crystal structures and identification of potential styrylthieno[2,3-
El Bakri Y; Ahmad B; Saravanan K; Ahmad I; Bakhite EA; Younis O; Al-Waleedy SAH; Ibrahim OF; Nafady A; Mague JT; Mohamed SK
J Biomol Struct Dyn; 2024 May; 42(8):4325-4343. PubMed ID: 37318002
[TBL] [Abstract][Full Text] [Related]
5. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
Ghosh A; Chakraborty M; Chandra A; Alam MP
J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
[TBL] [Abstract][Full Text] [Related]
7. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
[TBL] [Abstract][Full Text] [Related]
8. In Silico Identification and Validation of Organic Triazole Based Ligands as Potential Inhibitory Drug Compounds of SARS-CoV-2 Main Protease.
Sur VP; Sen MK; Komrskova K
Molecules; 2021 Oct; 26(20):. PubMed ID: 34684780
[TBL] [Abstract][Full Text] [Related]
9. Identification of Pyrazole Derivatives of Usnic Acid as Novel Inhibitor of SARS-CoV-2 Main Protease Through Virtual Screening Approaches.
Roney M; Singh G; Huq AKMM; Forid MS; Ishak WMBW; Rullah K; Aluwi MFFM; Tajuddin SN
Mol Biotechnol; 2024 Apr; 66(4):696-706. PubMed ID: 36752937
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the effects of chlorhexidine and several flavonoids as antiviral purposes on SARS-CoV-2 main protease: molecular docking, molecular dynamics simulation studies.
Tatar G; Salmanli M; Dogru Y; Tuzuner T
J Biomol Struct Dyn; 2022 Oct; 40(17):7656-7665. PubMed ID: 33749547
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of novel 3C-like protease inhibitors as lead compounds against SARS-CoV-2.
Yan Y; Liu H; Wu D; Gu Z; Guo W; Yao H; Lin K; Li X
Future Med Chem; 2024; 16(9):887-903. PubMed ID: 38618977
[TBL] [Abstract][Full Text] [Related]
12. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.
Rai H; Barik A; Singh YP; Suresh A; Singh L; Singh G; Nayak UY; Dubey VK; Modi G
Mol Divers; 2021 Aug; 25(3):1905-1927. PubMed ID: 33582935
[TBL] [Abstract][Full Text] [Related]
13. Computational guided identification of a citrus flavonoid as potential inhibitor of SARS-CoV-2 main protease.
Gogoi N; Chowdhury P; Goswami AK; Das A; Chetia D; Gogoi B
Mol Divers; 2021 Aug; 25(3):1745-1759. PubMed ID: 33236176
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel inhibitors of SARS-CoV-2 main protease (M
Verma S; Patel CN; Chandra M
J Comput Chem; 2021 Oct; 42(26):1861-1872. PubMed ID: 34287986
[TBL] [Abstract][Full Text] [Related]
15. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
Abdizadeh R; Hadizadeh F; Abdizadeh T
Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
[TBL] [Abstract][Full Text] [Related]
16. In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors.
Ibrahim MAA; Abdelrahman AHM; Allemailem KS; Almatroudi A; Moustafa MF; Hegazy MF
Protein J; 2021 Jun; 40(3):296-309. PubMed ID: 33387249
[TBL] [Abstract][Full Text] [Related]
17. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL
Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ
Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621
[TBL] [Abstract][Full Text] [Related]
18. Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease.
Marinho EM; Batista de Andrade Neto J; Silva J; Rocha da Silva C; Cavalcanti BC; Marinho ES; Nobre Júnior HV
Microb Pathog; 2020 Nov; 148():104365. PubMed ID: 32619669
[TBL] [Abstract][Full Text] [Related]
19. Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay.
Pitsillou E; Liang J; Ververis K; Hung A; Karagiannis TC
J Mol Graph Model; 2021 May; 104():107851. PubMed ID: 33556646
[TBL] [Abstract][Full Text] [Related]
20. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays.
Gupta Y; Maciorowski D; Zak SE; Jones KA; Kathayat RS; Azizi SA; Mathur R; Pearce CM; Ilc DJ; Husein H; Herbert AS; Bharti A; Rathi B; Durvasula R; Becker DP; Dickinson BC; Dye JM; Kempaiah P
Methods; 2021 Nov; 195():57-71. PubMed ID: 33453392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
